Tritium labelled (±)‐7‐chloro‐8‐hydroxy‐3‐methyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (SCH23390)

Steven D. Wyrick, Richard B. Mailman

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


The antipsychotic drug, SCH23390, once thought to be the first selective D1 dopamine antagonist, is now believed to possibly produce its profound antidopaminergic and antipsychotic effects via molecular sites that involve recognition characteristics similar to, or are a subpopulation of the D1 dopamine receptors. Tritium labelled SCH23390 has been prepared in our laboratory by palladium catalyezed reductive aryl debromination of a brominated precursor with carrier free tritium gas in THF. The product is labelled in the 9‐position of the benzazepine ring and a specific activity of 5.6 Ci/mmole was obtained.

Original languageEnglish (US)
Pages (from-to)189-195
Number of pages7
JournalJournal of Labelled Compounds and Radiopharmaceuticals
Issue number2
StatePublished - Feb 1985

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry
  • Radiology Nuclear Medicine and imaging
  • Drug Discovery
  • Spectroscopy
  • Organic Chemistry


Dive into the research topics of 'Tritium labelled (±)‐7‐chloro‐8‐hydroxy‐3‐methyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (SCH23390)'. Together they form a unique fingerprint.

Cite this